Crystallographic Fragment Screening of the Dengue Virus Polymerase Reveals Multiple Binding Sites for the Development of Non-nucleoside Antiflavivirals

Dengue viruses (DENVs) infect approximately 400 million people each year, and currently, there are no effective therapeutics available. To explore potential starting points for antiviral drug development, we conducted a large-scale crystallographic fragment screen targeting the RNA-dependent RNA polymerase (RdRp) domain of the nonstructural protein 5 (NS5) from DENV serotype 2. Our screening, which involved 1108 fragments, identified 60 hit compounds across various known binding sites, including the active site, N pocket, and RNA tunnel. Additionally, we discovered a novel binding site and a fragment-binding hot spot in thumb site II. These structural findings open amenable avenues for developing non-nucleoside inhibitors and offer valuable insights for future structure-based drug design aimed at DENV and other flaviviral RdRps.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-09-02
DOI
https://doi.org/10.1021/acs.jmedchem.5c01014
Citations
1
Primary Topic
Mosquito-borne diseases and control
Type
article
Field-Weighted Citation Impact
1.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Crystallographic Fragment Screening of the Dengue Virus Polymerase Reveals Multiple Binding Sites for the Development of Non-nucleoside Antiflavivirals

Blake Balcomb, Francesc X. Ruiz, Anu V. Chandran, Ashima Chopra et al.
1 citations
Journal of Medicinal Chemistry
Mosquito-borne diseases and control
1.88
article

Crystallographic Fragment Screening of the Dengue Virus Polymerase Reveals Multiple Binding Sites for the Development of Non-nucleoside Antiflavivirals

Blake Balcomb, Francesc X. Ruiz, Anu V. Chandran, Ashima Chopra, F. von Delft, J.C. Aschenbrenner, Manisha Saini, Eddy Arnold, D. Fearon, Peter Marples
article en
1 citations

Abstract

Dengue viruses (DENVs) infect approximately 400 million people each year, and currently, there are no effective therapeutics available. To explore potential starting points for antiviral drug development, we conducted a large-scale crystallographic fragment screen targeting the RNA-dependent RNA polymerase (RdRp) domain of the nonstructural protein 5 (NS5) from DENV serotype 2. Our screening, which involved 1108 fragments, identified 60 hit compounds across various known binding sites, including the active site, N pocket, and RNA tunnel. Additionally, we discovered a novel binding site and a fragment-binding hot spot in thumb site II. These structural findings open amenable avenues for developing non-nucleoside inhibitors and offer valuable insights for future structure-based drug design aimed at DENV and other flaviviral RdRps.

Journal of Medicinal ChemistryVol. 68(17)
Rutgers, The State University of New Jersey (US), Nuffield Orthopaedic Centre (GB), Diamond Light Source (GB), Advanced Pharma (US), Research Complex at Harwell (GB)
Diamond Light Source, National Institutes of Health, National Institute of Allergy and Infectious Diseases
Openalex Percentile: Top 12%
Mosquito-borne diseases and control
1.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.